Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen/UCB Poised For Osteoporosis Drug Filing On Back Of Mixed PhIII

This article was originally published in Scrip

Executive Summary

Amgen Inc. and partner UCB will file their osteoporosis drug romosozumab this year on the back of mostly positive Phase III data in postmenopausal women – but where will the drug be positioned against Amgen's own Prolia (denosumab) and other available treatments?


Related Content

Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review
US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request
Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts